Ascendis Pharma A (ASND) Depreciation & Amortization (CF) (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Depreciation & Amortization (CF) data on file, last reported at $4.9 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 3.34% year-over-year to $4.9 million; the trailing twelve-month figure through Mar 2026 stood at $19.7 million (up 5.28% YoY), and the FY2025 full-year result was $20.0 million, up 7.29% from the prior year.
• Depreciation & Amortization (CF) retreated to $4.9 million in Q1 2026, from $5.5 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.5 million in Q4 2025 to a low of $4.4 million in Q3 2022.
• A 5-year average of $4.8 million and a median of $4.7 million in 2025 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) declined 10.37% in 2024 and rose 17.41% in 2025, its largest moves.
• Tracing ASND's Depreciation & Amortization (CF) over 5 years: stood at $4.6 million in 2022, then grew by 12.47% to $5.2 million in 2023, then retreated by 10.37% to $4.7 million in 2024, then gained by 17.41% to $5.5 million in 2025, then retreated by 9.6% to $4.9 million in 2026.
• Business Quant data shows ASND's Depreciation & Amortization (CF) at $4.9 million in Q1 2026, $5.5 million in Q4 2025, and $4.6 million in Q3 2025.